Octreotide Pamoate
Esophageal Varices
Shanghai Zhongshan HospitalPhase 4 / ApprovedDormant
BB
71/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the Esophageal Varices cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PROPRANOLOL West China Hospital | Phase 4 | BBB |
CARVEDILOL West China Hospital | Phase 4 | BBB |
GLY-GLY-GLY-CYS-TYR-PHE-GLN-ASN-CYS-PRO-LYS-GLY-NH2 (4-9 DISULFIDE) General Hospital of Shenyang Military Region | Phase 4 | BB |
Octreotide Pamoate Shanghai Zhongshan Hospital | Phase 4 | BB |
Apixaban Asian Institute Of Medical Sciences | Phase 4 | BB |
View all 21 →
Same molecule, other indications
Octreotide Pamoate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →